Abstracts tagged "Gout and renal disease"

Abstract Number: 1957 • 2016 ACR/ARHP Annual Meeting
No Increased Risk of Chronic Kidney Disease with Allopurinol Use
Ana Beatriz Vargas-Santos¹, Christine Peloquin², Yuqing Zhang³ and Tuhina Neogi¹, ¹Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ²Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA, ³Clinical Epidemiology and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Chronic kidney disease (CKD) is a cause and consequence of hyperuricemia. While clinicians are often cautious about using allopurinol in patients with CKD, there…
Abstract Number: 166 • 2012 ACR/ARHP Annual Meeting
Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Vs Normal Renal Function
Michael DeBerardine¹, Mark C. Fisher², Robert T. Keenan³, Michael H. Pillinger⁴ and Daria B. Crittenden⁴, ¹NYU School of Medicine, Division of Rheumatology, New York, NY, ²Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Boston, MA, ³Rheumatology, Duke University, Durham, NC, ⁴Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Patients with chronic kidney disease (CKD) may be at increased risk for allopurinol (ALLO) hypersensitivity, possibly because impaired renal excretion causes accumulation of the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].